Oz: Codifying MFN Deals Could Avert ‘Draconian’ Pricing Measures

Why It Matters

Formalizing MFN agreements could lock in lower drug prices for Medicare, shaping the industry's revenue outlook while limiting future policymakers' ability to impose stricter pricing rules.

Key Takeaways

• Pfizer and CMS discussed confidential MFN pricing agreement.
• Terms of deal remain undisclosed to public.
• Oz aims to codify voluntary MFN deals into law.
• Codification intended to prevent harsher future pricing mandates.
• Industry sees potential revenue impact and regulatory certainty.

Pulse Analysis

Most‑favored‑nation (MFN) agreements have emerged as a voluntary tool for the Centers for Medicare & Medicaid Services (CMS) to secure the lowest commercial price a drug manufacturer offers any payer. By tying Medicare reimbursements to the best price available in the private market, MFNs aim to curb the steep growth in prescription‑drug spending without imposing direct price caps. The approach gained traction after Congress limited CMS’s ability to negotiate prices, prompting the agency to explore alternative levers that preserve patient access while delivering fiscal savings.

On Feb. 17, Pfizer chief Albert Bourla met directly with CMS Administrator Mehmet Oz to discuss a new MFN arrangement, though the contract’s specifics remain confidential. Oz announced that the Trump administration intends to codify these voluntary deals into statutory law, arguing that such a framework would shield Medicare from more ‘draconian’ pricing mandates that a future administration might impose. By embedding MFNs in legislation, policymakers hope to create a predictable pricing environment, reducing the incentive for abrupt regulatory overhauls and providing manufacturers with clearer market signals.

If codified, MFN deals could lock in lower reimbursement rates for Medicare, tightening the profit margins of high‑priced drugs while delivering measurable savings to the federal budget. Pharmaceutical firms, however, warn that mandatory MFNs may constrain pricing flexibility and could deter investment in innovative therapies. The move also signals a broader political strategy to pre‑empt more aggressive price‑control legislation, positioning voluntary agreements as a compromise between industry and lawmakers. Observers will watch how future administrations respond, especially if the codified MFN framework proves either effective or restrictive.